Royalty Pharma Plc (RPRX)
61.33
+0.02
(+0.03%)
USD |
NASDAQ |
Aug 24, 16:00
61.32
-0.01
(-0.02%)
After-Hours: 20:00
Royalty Pharma Debt to Equity Ratio : 1.312 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.312 |
| March 31, 2026 | 1.300 |
| December 31, 2025 | 1.384 |
| September 30, 2025 | 1.397 |
| June 30, 2025 | 1.263 |
| March 31, 2025 | 1.139 |
| December 31, 2024 | 1.096 |
| September 30, 2024 | 1.107 |
| June 30, 2024 | 1.174 |
| March 31, 2024 | 0.9446 |
| December 31, 2023 | 0.9401 |
| September 30, 2023 | 0.9987 |
| June 30, 2023 | 1.134 |
| March 31, 2023 | 1.196 |
| Date | Value |
|---|---|
| December 31, 2022 | 1.264 |
| September 30, 2022 | 1.156 |
| June 30, 2022 | 1.179 |
| March 31, 2022 | 1.229 |
| December 31, 2021 | 1.228 |
| September 30, 2021 | 1.224 |
| June 30, 2021 | 1.016 |
| March 31, 2021 | 1.192 |
| December 31, 2020 | 1.207 |
| September 30, 2020 | 1.306 |
| June 30, 2020 | 1.422 |
| March 31, 2020 | 1.154 |
| December 31, 2019 | 1.022 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| AstraZeneca PLC | 0.7166 |
| Johnson & Johnson | 0.5771 |
| Viatris, Inc. | 0.9555 |
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 19.82B |
| Total Liabilities (Quarterly) | 10.03B |
| Shareholders Equity (Quarterly) | 6.833B |
| Current Ratio | 2.797 |
| Net Debt Paydown Yield | -1.08% |